Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA2UYE)

Drug Name

Ro-24-7429 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Human immunodeficiency virus Tat protein (HIV tat)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[3]
ALX-40-4C	DMV934L	Human immunodeficiency virus infection	1C62	Phase 2	[4]
Anti-HIV ribozyme therapy	DMQZJ3B	Human immunodeficiency virus infection	1C62	Phase 1/2	[5]
EM-2487	DMG9R8E	Human immunodeficiency virus infection	1C62	Terminated	[6]
Durhamycin A	DM29PTO	Discovery agent	N.A.	Investigative	[7]
CGP 40336A	DMEA5BZ	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Tat protein (HIV tat)	TTT3ZC9	TAT_HV1H2	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00002314) A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma. U.S. National Institutes of Health.
2	A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J Infect Dis. 1995 Nov;172(5):1246-52.
3	Docking studies reveal a selective binding of D-penicillamine to the transactivator protein of human immunodeficiency virus type 1. FEBS Lett. 2002 Apr 10;516(1-3):43-6.
4	Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. J Virol. 1996 May;70(5):2825-31.
5	Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS. Methods Mol Biol. 2004;252:581-98.
6	EM2487, a novel anti-HIV-1 antibiotic, produced by Streptomyces sp. Mer-2487: taxonomy, fermentation, biological properties, isolation and structure elucidation. J Antibiot (Tokyo). 1999 Nov;52(11):971-82.
7	Durhamycin A, a potent inhibitor of HIV Tat transactivation. J Nat Prod. 2002 Aug;65(8):1091-5.
8	RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86.